tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
PremiumThe FlyQ32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
24d ago
Q32 Bio sells complement inhibitor ADX-097 to Akebia
Premium
The Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia
24d ago
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts
Premium
Company Announcements
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts
1M ago
Eight option delistings on August 18th
PremiumThe FlyEight option delistings on August 18th
4M ago
Q32 Bio Inc. Advances Alopecia Areata Treatment with Phase 2a Trial of Bempikibart
Premium
Company Announcements
Q32 Bio Inc. Advances Alopecia Areata Treatment with Phase 2a Trial of Bempikibart
4M ago
Q32 Bio Inc. Reports Continued Losses Amid Development Efforts
Premium
Company Announcements
Q32 Bio Inc. Reports Continued Losses Amid Development Efforts
5M ago
Q32 Bio Inc. Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsQ32 Bio Inc. Reports Q1 2025 Financial Results
8M ago
Q32 Bio granted Fast Track designation for bempikibart
Premium
The Fly
Q32 Bio granted Fast Track designation for bempikibart
8M ago
Q32 Bio Board Member Mark Iwicki Resigns
Premium
Company Announcements
Q32 Bio Board Member Mark Iwicki Resigns
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100